MetaCap

Celcuity Inc. (CELC)

NASDAQ: CELCHealth CareMedical SpecialitiesUSD

53.35-2.96 (-5.26%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CELC stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.72
52-week range
53.20 – 151.02
Day range
53.20 – 57.00
Volume / Avg
636.53K / 1.25M
Beta
—

52-week range

$53.20$151.02

CELC stock today

Shares of Celcuity (CELC) finished lower on Nov 20 at $53.35, a drop of 5.26% or $2.96 per share, versus the S&P 500's 3.70% decline. Shares are 64.7% below their 52-week high of $151.02, set on May 4, 2026 and 0.3% above the 52-week low of $53.20, near the bottom of the past year's range. CELC is down 46.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.3%.

Celcuity has posted a net loss over the last twelve months (EPS of -$4.72), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Celcuity

Company profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc.

Industry
Medical Specialities
CEO
Mr. Brian F. Sullivan
Headquarters
Minneapolis, MN
Employees
155
IPO year
2017

Financial highlights

Full financials

Celcuity reported a net loss of $177.0 million, compared with a loss of $111.8 million a year earlier. Diluted earnings per share came in at -$3.79.

Celcuity annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-177.04M$-111.78M$-63.78M$-40.37M$-29.61M
EPS (diluted)$-3.79$-2.83$-2.69$-2.64$-2.21

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$150.85+182.76%

  • Strong buy 3
  • Buy 10
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $130.00High $177.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.33 vs $-1.47
Surprise
+9.52%

CELC news

All CELC news

Celcuity peers

Health Care sector
CELC peer companies
CompanyPrice% ChgMarket capCompare
VCYTVeracyte Inc.25.13+0.36%$2.03Bvs CELC
ACHCAcadia Healthcare Company Inc.34.60+0.38%$3.22Bvs CELC
CLOVClover Health Investments Corp. Class A3.73-1.06%$2.00Bvs CELC
FTREFortrea Holdings Inc.18.55-7.94%$1.79Bvs CELC
PSNLPersonalis Inc.14.27-3.06%$1.55Bvs CELC
CDNACareDx Inc.70.00-2.67%$3.68Bvs CELC
TRUPTrupanion Inc.35.56-0.86%$1.54Bvs CELC
LMRILumexa Imaging Holdings Inc.14.26+1.42%$1.37Bvs CELC

Indexes, lists and sector

Celcuity stock FAQ

What is Celcuity's stock price today?

CELC last traded at $53.35 as of Nov 20, 4:00 PM EST, down 5.26% on the day. Prices are delayed at least 15 minutes.

Who is Celcuity's CEO?

Mr. Brian F. Sullivan is the chief executive officer of Celcuity Inc., which has about 155 employees.

What is the CELC 52-week high?

The 52-week high for CELC is $151.02 and the 52-week low is $53.20. The stock is currently 64.7% below its high.

Compare CELC